Iterum Therapeutics plc
ITRMNASDAQHealthcare
$0.03
$-0.00(-10.98%)
Market Cap$1598747
P/E Ratio—
52W High$1.42
52W Low$0.0271
Iterum Therapeutics plc (ITRM) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ITRM · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2025Report Date: Nov 14, 2025EPS Actual
-$0.20
Est. -$0.13 · -53.9%
Revenue
$0.00B
Fiscal Period
Q4 FY2025
FY ends December
Report Date
Nov 14, 2025
After Market Close
▼ Miss EPS
ITRM reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.52
Rev. $3.34B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.52
Rev. Est.$3.34B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2026 | May 20, 2026 | -$0.10 | — | — | — | $0.00B | — |
| ◌ Q2 FY2026 | Apr 3, 2026 | -$0.14 | — | — | — | $0.00B | — |
| ▼ Q4 FY2025 | Nov 14, 2025 | -$0.13 | -$0.20 | -53.9% | $0.00B | — | — |
| ▼ Q3 FY2025 | Aug 5, 2025 | -$0.13 | -$0.16 | -23.1% | — | — | — |
| — Q2 FY2025 | May 13, 2025 | -$0.14 | -$0.14 | +0.0% | — | — | — |
| ▲ Q1 FY2025 | Feb 7, 2025 | -$0.24 | -$0.12 | +50.0% | — | $0.00B | — |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$0.23 | -$0.30 | -30.4% | — | — | — |
| ▲ Q3 FY2024 | Aug 14, 2024 | -$0.52 | -$0.30 | +42.3% | — | — | — |
Q2 FY2026
May 20, 2026
EPS Actual
—
EPS Est.
-$0.10
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 3, 2026
EPS Actual
—
EPS Est.
-$0.14
EPS Surpr.
—
Revenue
—
Q4 FY2025
Nov 14, 2025Miss
EPS Actual
-$0.20
EPS Est.
-$0.13
EPS Surpr.
-53.9%
Revenue
$0.00B
Q3 FY2025
Aug 5, 2025Miss
EPS Actual
-$0.16
EPS Est.
-$0.13
EPS Surpr.
-23.1%
Revenue
—
Q2 FY2025
May 13, 2025
EPS Actual
-$0.14
EPS Est.
-$0.14
EPS Surpr.
+0.0%
Revenue
—
Q1 FY2025
Feb 7, 2025Beat
EPS Actual
-$0.12
EPS Est.
-$0.24
EPS Surpr.
+50.0%
Revenue
—
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$0.30
EPS Est.
-$0.23
EPS Surpr.
-30.4%
Revenue
—
Q3 FY2024
Aug 14, 2024Beat
EPS Actual
-$0.30
EPS Est.
-$0.52
EPS Surpr.
+42.3%
Revenue
—
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2027 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2027 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q4 FY2025 | Nov 14, 2025 | -53.9% | $0.56 | $0.47 | -16.11% |
| ▼ Q3 FY2025 | Aug 5, 2025 | -23.1% | $0.71 | $0.70 | -2.58% |
| ▲ Q2 FY2025 | May 13, 2025 | +0.0% | $1.01 | $0.94 | -7.09% |
| ▲ Q1 FY2025 | Feb 7, 2025 | +50.0% | $1.49 | $1.43 | -4.03% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -30.4% | $1.43 | $1.36 | -4.90% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +42.3% | $1.17 | $1.21 | +3.42% |
| ▲ Q2 FY2024 | May 13, 2024 | +19.3% | $1.55 | $1.52 | -1.94% |
| ▲ Q1 FY2024 | Mar 28, 2024 | +7.8% | $1.59 | $1.54 | -3.14% |
Q4 FY2025-16.11%
Report Date
Nov 14, 2025
EPS Beat/Miss
-53.9%
Price Before
$0.56
Price After
$0.47
Q3 FY2025-2.58%
Report Date
Aug 5, 2025
EPS Beat/Miss
-23.1%
Price Before
$0.71
Price After
$0.70
Q2 FY2025-7.09%
Report Date
May 13, 2025
EPS Beat/Miss
+0.0%
Price Before
$1.01
Price After
$0.94
Q1 FY2025-4.03%
Report Date
Feb 7, 2025
EPS Beat/Miss
+50.0%
Price Before
$1.49
Price After
$1.43
Q4 FY2024-4.90%
Report Date
Nov 14, 2024
EPS Beat/Miss
-30.4%
Price Before
$1.43
Price After
$1.36
Q3 FY2024+3.42%
Report Date
Aug 14, 2024
EPS Beat/Miss
+42.3%
Price Before
$1.17
Price After
$1.21
Q2 FY2024-1.94%
Report Date
May 13, 2024
EPS Beat/Miss
+19.3%
Price Before
$1.55
Price After
$1.52
Q1 FY2024-3.14%
Report Date
Mar 28, 2024
EPS Beat/Miss
+7.8%
Price Before
$1.59
Price After
$1.54
Avg Beat Reaction-2.56%
Avg Miss Reaction-7.86%
Beat Rate5 / 8 quarters
Largest Move-16.11% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ITRM ends December
Iterum Therapeutics plc (ITRM) most recently reported earnings on November 14, 2025 for Q4 FY2025, posting EPS of $-0.20 — missing the analyst consensus of $-0.13 by -53.9%. The next ITRM earnings date is expected around September 1, 2026.
Each quarter, investors track ITRM earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ITRM revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ITRM's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ITRM earnings · 5 questionsIterum Therapeutics plc's next earnings report is expected around September 1, 2026. ITRM typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ITRM historically reports after market close (AMC).
ITRM earnings datewhen is ITRM earningsITRM next earnings datewhen does ITRM report earningsITRM earnings calendar
▸ Source: FMP · Iterum Therapeutics plc SEC filings · US GAAP · Iterum Therapeutics plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026